Akebia Vafseo for Anemia due to Chronic Kidney Disease OKd by FDA

 Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia 

Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care

Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET

Akebia will host a conference call on Thursday, March 28 at 8:00 a.m. Eastern Time to discuss the approval and planned next steps for launch. To access the call, please register by clicking on this Registration Link (https://register.vevent.com/register/BI8d947513ebdd4e32bf2fbc68d973108f), and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.

A live webcast of the conference call will be available via the "Investors" section of Akebia's website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia's website at https://ir.akebia.com approximately two hours after the event.

https://www.prnewswire.com/news-releases/akebia-receives-fda-approval-of-vafseo-vadadustat-tablets-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-on-dialysis-302101854.html